Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Isis Pharmaceuticals Inc

+ Add to Watchlist


69.3700 USD 0.7900 1.15%

As of 10:00:22 ET on 01/29/2015.

Snapshot for Isis Pharmaceuticals Inc (ISIS)

Open: 69.1100 Day's Range: 68.0600 - 70.2800 Volume: 440,256
Previous Close: 68.5800 52wk Range: 22.2500 - 75.2400 1-Yr Rtn: +42.11%

Stock Chart for ISIS

No chart data available.
  • ISIS:US 69.4699
  • 1D
  • 1M
  • 1Y
Interactive ISIS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ISIS

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.8182
Est. EPS (USD) (12/2014) -0.5620
Est. PEG Ratio -
Market Cap (M USD) 8,102.12
Shares Outstanding (M) 118.14
30 Day Average Volume 3,886,029
Price/Book (mrq) 23.7625
Price/Sale (ttm) 47.4394
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ISIS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ISIS

Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.

Stanley T Crooke "Stan"Chairman/President/CEO/FounderB Lynne ParshallCOO/Secretary
Sarah BoyceChief Business OfficerElizabeth L HougenSenior VP:Finance/CFO
More Company Profile & Key Executives for ISIS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil